Drug delivery systems, CNS protection, and the blood brain barrier

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Upadhyay, Ravi Kant ^a  

^a D D U GORAKHPUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIPORTER; BETA CYCLODEXTRIN; CARBON NANOTUBE; CHITOSAN; CHOLESTEROL; DENDRIMER; DRUG CARRIER; DRUG VEHICLE; IMMUNOGLOBULIN; LIPOSOME; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NANOPARTICLE; NANOTUBE; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; PEPTIDE; PRODRUG; PROLINE RICH PROTEIN; PROTEIN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TANNIN; VANCOMYCIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN PROTECTION; BRAIN VENTRICULITIS; CANCER THERAPY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; CENTRAL NERVOUS SYSTEM PROTECTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; MENINGITIS; MICELLE; MICROBUBBLE; NEUROLOGIC DISEASE; NONHUMAN; PAIN; REVIEW; TRANSDERMAL DRUG DELIVERY SYSTEM; ULTRASOUND; UNSPECIFIED SIDE EFFECT; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY; DRUG EFFECTS; PATHOLOGY;

BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; CHITOSAN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES;

EID: 84911881604     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/869269     Document Type: Review

References (311)

1. M. Kinoshita, "Targeted drug delivery to the brain using focused ultrasound," Topics in Magnetic Resonance Imaging, Vol. 17, No. 3, pp. 209-215, 2006.
2. A. R. Jones and E. V. Shusta, "Blood-brain barrier transport of therapeutics via receptor-mediation," Pharmaceutical Research, Vol. 24, No. 9, pp. 1759-1771, 2007.
3. S. Senel, M. Kremer, K. Nagy, and C. Squier, "Delivery of bio-active peptides and proteins across oral (Buccal) mucosa," Current Pharmaceutical Biotechnology, Vol. 2, No. 2, pp. 175-186, 2001.
4. A. G. de Boer, I. C. J. van der Sandt, and P. J. Gaillard, "The role of drug transporters at the blood-brain barrier," Annual Review of Pharmacology and Toxicology, Vol. 43, pp. 629-656, 2003.
5. M. P. Schaddelee, H. L. Voorwinden, D. Groenendaal et al., "Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships," European Journal of Pharmaceutical Sciences, Vol. 20, No. 3, pp. 347-356, 2003.
6. K. M. Huttunen and J. Rautio, "Prodrugs-an efficient way to breach delivery and targeting barriers," Current Topics in Medicinal Chemistry, Vol. 11, No. 18, pp. 2265-2287, 2011.
7. A. Seelig, R. Gottschlich, and R. M. Devant, "A method to determine the ability of drugs to difuse through the blood-brain barrier," Proceedings of the National Academy of Sciences of the United States of America, Vol. 91, No. 1, pp. 68-72, 1994.
8. M. Dadparvar, S. Wagner, S. Wien et al., "HI 6 human serum albumin nanoparticles-development and transport over an in vitro blood-brain barrier model," Toxicology Letters, Vol. 206, No. 1, pp. 60-66, 2011.
9. I. Tamai and A. Tsuji, "Drug delivery through the blood-brain barrier," Advanced Drug Delivery Reviews, Vol. 19, No. 3, pp. 401-424, 1996.
10. M. A. Bellavance, M. Blanchette, and D. Fortin, "Recent advances in blood-brain barrier disruption as a CNS delivery strategy," The AAPS Journal, Vol. 10, No. 1, pp. 166-177, 2008.
11. O. Kuittinen, T. Siniluoto, M. Isokangas et al., "Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma," Duodecim, Vol. 129, No. 15, pp. 1563-1570, 2013.
12. K. K. Jain, "Nanobiotechnology-based strategies for crossing the blood-brain barrier," Nanomedicine, Vol. 7, No. 8, pp. 1225-1233, 2012.
13. P. J. Gaillard, "Crossing barriers from blood-to-brain and aca-demia-to-industry," Terapeutic Delivery, Vol. 1, No. 4, pp. 495-500, 2010.
14. J. Bian-Sheng, J. Cen, L. Liu, and L. He, "In vitro and in vivo study of dodichyl phosphate on the efflux of P-glycoprotein at the blood brain barrier," International Journal of Developmental Neuroscience, Vol. 31, No. 8, pp. 828-835, 2013.
15. D. Secko, "Breaking down the blood-brain barrier," Canadian Medical Association Journal, Vol. 174, No. 4, pp. 448-448, 2006.
16. J. Kreuter, "Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?" Advances in Drug Delivery Reviews, Vol. 71, pp. 2-14, 2013.
17. Q. Weng, B. Wang, X. Wang et al., "Highly water-soluble, porous, and biocompatible boron nitrides for anticancer drug delivery," ACS Nano, 2014.
18. M. S. Kim, D. W. Lee, K. Park et al., "Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-con-jugated thermosensitive liposomes," Colloids and Surfaces B: Biointerfaces, Vol. 1, No. 116, pp. 17-25, 2014.
19. J. Naskar, S. Roy, A. Joardar, S. Das, and A. Banerjee, "Self-assembling dipeptide-based nontoxic vesicles as carriers for drugs and other biologically important molecules," Organic and Biomolecular Chemistry, Vol. 9, No. 19, pp. 6610-6615, 2011.
20. N. S. Ningaraj, M. Rao, and K. L. Black, "Calcium-dependent potassium channels as a target protein for modulation of the blood-brain tumor barrier," Drug News and Perspectives, Vol. 16, No. 5, pp. 291-298, 2003.
21. N. S. Ningaraj, M. Rao, K. Hashizume, K. Asotra, and K. L. Black, "Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels," Journal of Pharmacology and Experimental Terapeutics, Vol. 301, No. 3, pp. 838-851, 2002.
22. N. S. Ningaraj, M. K. Rao, and K. L. Black, "Adenosine 5'-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model," Cancer Research, Vol. 63, No. 24, pp. 8899-8911, 2003.
23. J. Rautio and P. J. Chikhale, "Drug delivery systems for brain tumor therapy," Current Pharmaceutical Design, Vol. 10, No. 12, pp. 1341-1353, 2004.
24. A. B. Etame, R. J. Diaz, C. A. Smith, T. G. Mainprize, K. Hynynen, and J. T. Rutka, "Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology," Neurosurgical Focus, Vol. 32, No. 1, p. E3, 2012.
25. H. Liu, H. Yang, M. Hua, and K. Wei, "Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: an overview of the current preclinical status," Neurosurgical focus, Vol. 32, No. 1, article E4, 2012.
26. J. Blakeley, "Drug delivery to brain tumors," Current Neurology and Neuroscience Reports, Vol. 8, No. 3, pp. 235-241, 2008.
27. K. L. Black and N. S. Ningaraj, "Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor," Cancer Control, Vol. 11, No. 3, pp. 165-173, 2004.
28. R. D. Fross, P. C. Warnke, and D. R. Groothuis, "Blood flow and blood-to-tissue transport in 9L gliosarcomas: the role of the brain tumor model in drug delivery research," Journal of Neuro-Oncology, Vol. 11, No. 3, pp. 185-197, 1991.
29. A. Weyerbrock, S. Walbridge, J. E. Saavedra, L. K. Keefer, and E. H. Oldfeld, "Diferential efects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas," Neuro-Oncology, Vol. 13, No. 2, pp. 203-211, 2011.
30. A. Weyerbrock, S. Walbridge, R. M. Pluta, J. E. Saavedra, L. K. Keefer, and E. H. Oldfeld, "Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas," Journal of Neurosurgery, Vol. 99, No. 4, pp. 728-737, 2003.
31. M. M. Yallapu, S. F. Othman, E. T. Curtis, B. K. Gupta, M. Jaggi, and S. C. Chauhan, "Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy," Biomaterials, Vol. 32, No. 7, pp. 1890-1905, 2011.
32. B. T. Hunter, "Breaching the brain's security system," Consumers' Research Magazine, Vol. 84, No. 2, p. 21, 2001.
33. P. Hsieh, C. Hung, and J. Fang, "Current prodrug design for drug discovery," Current Pharmaceutical Design, Vol. 15, No. 19, pp. 2236-2250, 2009.
34. J. Rautio, H. Kumpulainen, T. Heimbach et al., "Prodrugs: design and clinical applications," Nature Reviews Drug Discovery, Vol. 7, No. 3, pp. 255-270, 2008.
35. J. B. Zawilska, J. Wojcieszak, and A. B. Olejniczak, "Prodrugs: a challenge for the drug development," Pharmacological Reports, Vol. 65, No. 1, pp. 1-14, 2013.
36. J. Rautio, K. Laine, M. Gynther, and J. Savolainen, "Prodrug approaches for CNS delivery," AAPS Journal, Vol. 10, No. 1, pp. 92-102, 2008.
37. L. Hu, "Prodrugs: effective solutions for solubility, permeability and targeting challenges," IDrugs, Vol. 7, No. 8, pp. 736-742, 2004.
38. J. Brask, F. Albericio, and K. J. Jensen, "Fmoc solid-phase synthesis of peptide thioesters by masking as trithioortho esters," Organic Letters, Vol. 5, No. 16, pp. 2951-2953, 2003.
39. A. Novak, B. Binnington, B. Ngan, K. Chadwick, N. Fleshner, and C. A. Lingwood, "Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunode-tection in human cancer biopsies," Glycobiology, Vol. 23, No. 11, pp. 1230-1239, 2013.
40. M. S. Parker, R. Sah, and S. L. Parker, "Surface masking shapes the traffic of the neuropeptide y Y2 receptor," Peptides, Vol. 37, No. 1, pp. 40-48, 2012.
41. W. M. Pardridge, D. Wu, and T. Sakane, "Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain up take of brain-derived neurotrophic factor following intravenous administration," Pharmaceutical Research, Vol. 15, No. 4, pp. 576-582, 1998.
42. W. M. Pardridge, "Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids," Neurochemical Research, Vol. 23, No. 5, pp. 635-644, 1998.
43. W. M. Pardridge, "CNS drug design based on principles of blood-brain barrier transport," Journal of Neurochemistry, Vol. 70, No. 5, pp. 1781-1792, 1998.
44. J. M. Yoffey, "Passage of fluid and other substances through the nasal mucosa," The Journal of Laryngology and Otology, Vol. 72, No. 5, pp. 377-384, 1958.
45. J. Ali, M. Ali, S. Baboota, J. K. Sahni, C. Ramassamy, and L. D. Bhavna, "Potential of nanoparticulate drug delivery systems by intranasal administration," Current Pharmaceutical Design, Vol. 16, No. 14, pp. 1644-1653, 2010.
46. H. R. Costantino, L. Illum, G. Brandt, P. H. Johnson, and S. C. Quay, "Intranasal delivery: physicochemical and therapeutic aspects," International Journal of Pharmaceutics, Vol. 337, No. 1-2, pp. 1-24, 2007.
47. A. J. Landau, R. T. Eberhardt, and W. H. Frishman, "Intranasal delivery of cardiovascular agents: sn innovative approach to cardiovascular pharmacotherapy," American Heart Journal, Vol. 127, No. 6, pp. 1594-1599, 1994.
48. R. T. Jackson, J. Tigges, and W. Arnold, "Subarachnoid space of the CNS, nasal mucosa, and lymphatic system," Archives of Otolaryngology, Vol. 105, No. 4, pp. 180-184, 1979.
49. L. Illum, "Is nose-to-brain transport of drugs in man a reality?" Journal of Pharmacy and Pharmacology, Vol. 56, No. 1, pp. 3-17, 2004.
50. T. Yamada, "The potential of the nasal mucosa route for emergency drug administration via a high-pressure needleless injection system," Anesthesia Progress, Vol. 51, No. 2, pp. 56-61, 2004.
51. G. Rathnam, N. Narayanan, and R. Ilavarasan, "Carbopol-based gels for nasal delivery of progesterone," AAPS PharmSciTech, Vol. 9, No. 4, pp. 1078-1082, 2008.
52. + profoundly decreases brain injury in a rat model of transient focal ischemia," Frontiers in Bioscience, Vol. 12, No. 7, pp. 2728-2734, 2007.
53. G. Wei, D. Wang, H. Lu et al., "Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury," Frontiers in Bioscience, Vol. 12, No. 13, pp. 4986-4996, 2007.
54. T. K. Vyas, A. Shahiwala, S. Marathe, and A. Misra, "Intranasal drug delivery for brain targeting," Current Drug Delivery, Vol. 2, No. 2, pp. 165-175, 2005.
55. J. C. G. Garcia-Rodriguez and I. Sosa-Teste, "The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans," TheScientific-World Journal, Vol. 9, pp. 970-981, 2009.
56. B. E. Bleske, E. W. Warren, T. L. Rice, M. J. Shea, G. Amidon, and P. Knight, "Comparison of intravenous and intranasal administration of epinephrine during CPR in a canine model," Annals of Emergency Medicine, Vol. 21, No. 9, pp. 1125-1130, 1992.
57. W. Chieny, K. S. E. Su, and S. F. Chang, Nasal Systemic Drug Delivery, Drugs and the Pharmaceutical Sciences, Marcel Dekker, New York, NY, USA, 1989.
58. 3-octreotate," Dalton Transactions, Vol. 43, No. 3, pp. 1386-1396, 2013.
59. E. M. Cornford and M. E. Cornford, "New systems for delivery of drugs to the brain in neurological disease," Lancet Neurology, Vol. 1, No. 5, pp. 306-315, 2002.
60. B. Jodeiry, M. Heidarzadeh, S. Sahmani-Asl et al., "Study of intraventricular hemorrhage in VLBW neonates admitted in Al-Zahra Hospital, Tabriz, Iran. Niger," Nigerian Journal of Medicine, Vol. 21, No. 1, pp. 92-97, 2012.
61. R. J. Boado, Y. Zhang, Y. Wang, and W. M. Pardridge, "GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier," Biotechnology and Bioengineering, Vol. 100, No. 2, pp. 387-396, 2008.
62. J. M. Zhang, X. M. Zhao, S. J. Wang et al., "Evaluation of 99mTc-peptide-ZHER2:342 Afbody molecule for in vivo molecular imaging," The British Journal of Radiology, Vol. 87, No. 1033, Article ID 20130484, 2014.
63. X. Cui, D. Cao, Z. Wang, and A. Zheng, "Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration," Pharmazie, Vol. 68, No. 1, pp. 69-74, 2013.
64. F. Derakhshan and C. Toth, "Insulin and the brain," Current Diabetes Reviews, Vol. 9, No. 2, pp. 102-116, 2013.
65. M. Grapp, A. Wrede, M. Schweizer et al., "Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma," Nature Communications, Vol. 4, article 3123, 2013.
66. C. Kadoch, J. Li, V. S. Wong et al., "Complement activation and intraventricular rituximab distribution in recurrentcentral nervous system lymphoma," Clinical Cancer Research, Vol. 20, No. 4, pp. 1029-1041, 2014.
67. A. Zechariah, A. ElAli, T. R. Doeppner et al., "Vascular endo-thelial growth factor promotes pericyte coverage of brain capillaries, improves cerebral blood flow during subsequent focal cerebral ischemia, and preserves the metabolic penumbra," Stroke, Vol. 44, No. 6, pp. 1690-1697, 2013.
68. M. S. Byerly, R. D. Swanson, N. N. Semsarzadeh et al., "Identification of hypothalamic neuron-derived neurotrophic factor as a novel factor modulating appetite," American Journal of Physiology-Regulatory Integrative and Comparative Physiology, Vol. 304, No. 12, pp. R1085-R1095, 2013.
69. P. Fitchev, C. Chung, B. A. Plunkett, C. B. Brendler, and S. E. Crawford, "Pedf & stem cells: niche vs. nurture," Current Drug Delivery. In press.
70. K. Ng, V. H. Mabasa, I. Chow, and M. H. H. Ensom, "Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults," Neurocritical Care, Vol. 20, No. 1, pp. 158-171, 2014.
71. M. L. Brady, R. Raghavan, A. Alexander, K. Kubota, K. Sil-lay, and M. E. Emborg, "Pathways of influsate loss during convection-enhanced delivery into the putamen nucleus," Stereotactic and Functional Neurosurgery, Vol. 91, No. 2, pp. 69-78, 2013.
72. K. Nishina, H. Mizusawa, and T. Yokota, "Short interfering RNA and the central nervous system: development of nonviral delivery systems," Expert Opinion on Drug Delivery, Vol. 10, No. 3, pp. 289-292, 2013.
73. J. G. Schellinger, J. A. Pahang, R. N. Johnson et al., "Melittin-grafied HPMA-oligolysine based copolymers for gene delivery," Biomaterials, Vol. 34, No. 9, pp. 2318-2326, 2013.
74. I. M. Neelov, A. Janaszewska, B. Klajnert et al., "Molecular properties of lysine dendrimers and their interactions with aβ-peptides and neuronal cells," Current Medicinal Chemistry, Vol. 20, No. 1, pp. 134-143, 2013.
75. K. Li, H. Han, K. Zhu et al., "Real-time magnetic resonance imaging visualization and quantitative assessment of difusion in the cerebral extracellular space of C6 glioma-bearing rats," Neuroscience Letters, Vol. 543, pp. 84-89, 2013.
76. L. Albertazzi, L. Gherardini, M. Brondi et al., "In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry," Molecular Pharmaceutics, Vol. 10, No. 1, pp. 249-260, 2013.
77. A. Kurihara and W. M. Pardridge, "Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier," Cancer Research, Vol. 59, No. 24, pp. 6159-6163, 1999.
78. 111in chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradio-graphy with Alzheimer's disease brain sections," Bioconjugate Chemistry, Vol. 11, No. 3, pp. 380-386, 2000.
79. A. Kurihara, Y. Deguchi, and W. M. Pardridge, "Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharacokinetics, and in vivo imaging of experimental brain tumors," Bioconjugate Chemistry, Vol. 10, No. 3, pp. 502-511, 1999.
80. A. Mukherjee, U. Pandey, R. Chakravarty, H. D. Sarma, and A. Dash, "Development of Single vial kits for preparation of (68)Ga-labelled peptides for PET imaging of neuroendocrine tumours," Molecular Imaging and Biology, 2014.
81. J. Simeček, O. Zemek, P. Hermann, J. Notni, and H. J. Wester, "Tailored gallium(III) chelator NOPO: synthesis, characterization, bioconjugation, and application in preclinical Ga-68-PET imaging," Molecular Pharmaceutics, 2013.
82. P. Laverman, W. J. McBride, R. M. Sharkey, D. M. Goldenberg, and O. C. Boerman, "Al(18) F labeling of peptides and proteins," Journal of Labelled Compounds & Radiopharmaceuticals, Vol. 57, No. 4, pp. 219-223, 2014.
83. T. Reiner and B. M. Zeglis, "The inverse electron demand Diels-Alder click reaction in radiochemistry," Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 57, No. 7, pp. 285-290, 2013.
84. R. Bejot, J. Goggi, S. S. Moonshi, and E. G. Robins, "A practical synthesis of [18F]FtRGD: An angiogenesis biomarker for PET," Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 56, No. 2, pp. 42-49, 2013.
85. B. Barrios-Lopez, M. Raki, and K. Bergstrom, "Radiolabeled peptides for Alzheimer's diagnostic imaging: mini review," Current Radiopharmaceuticals, Vol. 6, No. 4, pp. 181-191, 2013.
86. X. Lu, L. Zhao, T. Xue, and H. Zhang, "Technetium-99m-Arg-Arg-Leu(g2), a modified peptide probe targeted to neovascular-ization in molecular tumor imaging," Journal of BUON, Vol. 18, No. 4, pp. 1074-1081, 2013.
87. Z. Ortiz-Arzate, C. L. Santos-Cuevas, B. E. Ocampo-García et al., "Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging," Nuclear Medicine Communications, Vol. 35, No. 4, pp. 423-432, 2014.
88. S. Maschauer, R. Haubner, T. Kuwert, and O. Prante, "(18)F-Glyco-RGD peptides for PET imaging of integrin expression: efficient radiosynthesis by click chemistry and modulation of biodistribution by glycosylation," Molecular Pharmaceutics, 2013.
89. M. Michaelides, S. A. Anderson, M. Ananth et al., "Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks," Journal of Clinical Investigation, Vol. 123, No. 12, pp. 5342-5350, 2013.
90. D. Zeng, Q. Ouyang, Z. Cai, X. Q. Xie, and C. J. Anderson, "New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides," Chemical Communications, Vol. 50, No. 1, pp. 43-45, 2014.
91. K. Kaira, H. Murakami, M. Endo et al., "Biological correlation of 8F-FDG uptake on PET in pulmonary neuroendocrine tumors," Anticancer Res, Vol. 33, No. 10, pp. 4219-28, 2013.
92. Y. Zhang and W. M. Pardridge, "Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin," Brain Research, Vol. 889, No. 1-2, pp. 49-56, 2001.
93. W. M. Pardridge, "Neurotrophins, neuroprotection and the blood-brain barrier," Current Opinion in Investigational Drugs, Vol. 3, No. 12, pp. 1753-1757, 2002.
94. D. Wu and W.M. Pardridge, "Neuroprotection withnoninvasive neurotrophin delivery to the brain," Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, No. 1, pp. 254-259, 1999.
95. F. Hefti, "Pharmacology of neurotrophic factors," Annual Review of Pharmacology and Toxicology, Vol. 37, pp. 239-267, 1997.
96. T. Sakane and W. M. Pardridge, "Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity," Pharmaceutical Research, Vol. 14, No. 8, pp. 1085-1091, 1997.
97. M. Brines, "What evidence supports use of erythropoietin as a novel neurotherapeutic?" Oncology, Vol. 16, supplement 10, No. 9, pp. 79-89, 2002.
98. S. Genc, T. F. Koroglu, and K. Genc, "Erythropoietin as a novel neuroprotectant," Restorative Neurology and Neuroscience, Vol. 22, No. 2, pp. 105-119, 2004.
99. N. L. Jumbe, "Erythropoietic agents as neurotherapeutic agents: what barriers exist?" Oncology, Vol. 16, No. 9, supplement 10, pp. 91-107, 2002.
100. I. Ulusal, R. Tari, G. Ozturk et al., "Dose-dependent ultrastructural and morphometric alterations after erythropoietin treatment in rat femoral artery vasospasm model," Acta Neurochirurgica, Vol. 152, No. 12, pp. 2161-2166, 2010.
101. T. C. Jackson, J. D. Verrier, and P. M. Kochanek, "Anthra-quinone-2-sulfonic acid (AQ2S) is a novel neurotherapeutic agent," Cell Death & Disease, Vol. 4, No. 1, article e451, 2013.
102. A. Sharma and H. S. Sharma, "Monoclonal antibodies as novel neurotherapeutic agents in CNS injury and repair," International Review of Neurobiology, Vol. 102, pp. 23-45, 2012.
103. X. Wang, J. P. de Rivero Vaccari, H. Wang et al., "Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective after spinal cord injury," Journal of Neurotrauma, Vol. 29, No. 5, pp. 936-945, 2012.
104. R. K. Stankovic, R. S. Chung, and M. Penkowa, "Metalloth-ioneins I and II: neuroprotective significance during CNS pathology," The International Journal of Biochemistry & Cell Biology, Vol. 39, No. 3, pp. 484-489, 2007.
105. L. Bica, P. J. Crouch, R. Cappai, and A. R. White, "Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease," Molecular BioSystems, Vol. 5, No. 2, pp. 134-142, 2008.
106. R. H. Ring, L. E. Schechter, S. K. Leonard et al., "Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist," Neuropharmacology, Vol. 58, No. 1, pp. 69-77, 2010.
107. K. N. Fargo, T. D. Alexander, L. Tanzer, A. Poletti, and K. J. Jones, "Androgen regulates neuritin mRNA levels in an in vivo model of steroid-enhanced peripheral nerve regeneration," Journal of Neurotrauma, Vol. 25, No. 5, pp. 561-566, 2008.
108. R. L. Frozza, A. Bernardi, J. B. Hoppe et al., "Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules," Molecular Neurobiology, Vol. 47, No. 3, pp. 1066-1080, 2013.
109. A. Sood and R. Panchagnula, "Peroral route: an opportunity for protein and peptide drug delivery," Chemical Reviews, Vol. 101, No. 11, pp. 3275-3303, 2001.
110. E. K. Hui, R. J. Boado, and W. M. Pardridge, "Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier," Molecular Pharmaceutics, Vol. 6, No. 5, pp. 1536-1543, 2009.
111. Y.-S. Kang, K. Voigt, and U. Bickel, "Stability of the disulfde bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells," Journal of Drug Targeting, Vol. 8, No. 6, pp. 425-434, 2000.
112. Q. Zhou, E. K. Hui, J. Z. Lu, R. J. Boado, and W. M. Pardridge, "Brain penetrating IgG-erythropoietin fusion protein is neu-roprotective following intravenous treatment in Parkinson's disease in the mouse," Brain Research, Vol. 1382, pp. 315-320, 2011.
113. K. Guillemyn, P. Kleczkowska, A. Novoa et al., "In vivo antinoci-ception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist: neurokinin 1 receptor antagonist chimera," Molecular Brain, Vol. 5, No. 1, article 4, 2012.
114. Q. H. Zhou, J. Z. Lu, E. K. Hui, R. J. Boado, and W. M. Pardridge, "Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein," Bioconjugate Chemistry, Vol. 22, No. 8, pp. 1611-1618, 2011.
115. I. Brasnjevic, H. W. M. Steinbusch, C. Schmitz, and P. Martinez-Martinez, "Delivery of peptide and protein drugs over the blood-brain barrier," Progress in Neurobiology, Vol. 87, No. 4, pp. 212-251, 2009.
116. U. Bickel, T. Yoshikawa, and W. M. Pardridge, "Delivery of pep-tides and proteins through the blood-brain barrier," Advanced Drug Delivery Reviews, Vol. 46, No. 1-3, pp. 247-279, 2001.
117. G. W. M. Vandermeulen and H. Klok, "Peptide/protein hybrid materials: Enhanced control of structure and improved performance through conjugation of biological and synthetic polymers," Macromolecular Bioscience, Vol. 4, No. 4, pp. 383-398, 2004.
118. N. M. Green, "Avidin," Advances in Protein Chemistry, Vol. 29, pp. 85-133, 1975.
119. N. McDannold, N. Vykhodtseva, S. Raymond, F. A. Jolesz, and K. Hynynen, "MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits," Ultrasound in Medicine and Biology, Vol. 31, No. 11, pp. 1527-1537, 2005.
120. K. Hynynen, N. McDannold, N. A. Sheikov, F. A. Jolesz, and N. Vykhodtseva, "Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications," NeuroImage, Vol. 24, No. 1, pp. 12-20, 2005.
121. K. Hynynen, N. McDannold, N. Vykhodtseva et al., "Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery," Journal of Neurosurgery, Vol. 105, No. 3, pp. 445-454, 2006.
122. H. L. Liu, H. W. Yang, M. Y. Hua, and K. Wei, "Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: an overview of the current preclini-cal status," Neurosurgical focus, Vol. 32, No. 1, article e4, 2012.
123. V. P. Torchilin, "Structure and design of polymeric surfactant-based drug delivery systems," Journal of Controlled Release, Vol. 73, No. 2-3, pp. 137-172, 2001.
124. C. H. Fan, C. Y. Ting, H. J. Lin et al., "SPIO-conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery," Biomaterials, Vol. 34, No. 14, pp. 3706-3715, 2013.
125. R. Alkins, A. Burgess, M. Ganguly et al., "Focused ultrasound delivers targeted immune cells to metastatic brain tumors," Cancer Research, Vol. 73, No. 6, pp. 1892-1899, 2013.
126. S. Huang, K. Shao, Y. Kuang et al., "Tumor targeting and microenvironment-responsive nanoparticles for gene delivery," Biomaterials, Vol. 34, No. 21, pp. 5294-5302, 2013.
127. M. C. Cochran, J. R. Eisenbrey, M. C. Soulen et al., "Disposition of ultrasound sensitive polymeric drug carrier in a rat hepato-cellular carcinoma model," Academic Radiology, Vol. 18, No. 11, pp. 1341-1348, 2011.
128. A. Mdzinarishvili, V. Sutariya, P. K. Talasila, W. J. Geldenhuys, and P. Sadana, "Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain stroke," Drug Delivery and Translational Research, Vol. 3, No. 4, pp. 309-317, 2013.
129. A. Iqbal, I. Ahmad, M. H. Khalid, M. S. Nawaz, S. H. Gan, and M. A. Kamal, "Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches," Journal of Environmental Science Health C: Environmental Carcinogenes and Ecotoxicology Review, Vol. 31, No. 3, pp. 256-284, 2013.
130. Q. Ye, L. Ye, X. Xu et al., "Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1α signaling pathway," BMC Complementary and Alternative Medicine, Vol. 28, No. 12, article 82, 2012.
131. S. Danjo, Y. Ishihara, M. Watanabe, Y. Nakamura, and K. Itoh, "Pentylentetrazole-induced loss of blood-brain barrier integrity involves excess nitric oxide generation by neuronal nitric oxide synthase," Brain Research, Vol. 1530, pp. 44-53, 2013.
132. N. G. Fisher, J. P. Christiansen, A. Klibanov, R. P. Taylor, S. Kaul, and J. R. Lindner, "Infuence of microbubble surface charge on capillary transit and myocardial contrast enhancement," Journal of the American College of Cardiology, Vol. 40, No. 4, pp. 811-819, 2002.
133. C. L. Graf and G. M. Pollack, "P-glycoprotein attenuates brain uptake of substrates after nasal instillation," Pharmaceutical Research, Vol. 20, No. 8, pp. 1225-1230, 2003.
134. J. M. Yoffey, "Passage of fluid and other substances through the nasal mucosa," The Journal of laryngology and otology, Vol. 72, No. 5, pp. 377-384, 1958.
135. M. Toborek, M. J. Seelbach, C. S. Rashid et al., "Voluntary exercise protects against methamphetamine-induced oxidative stress in brain microvasculature and disruption of the blood-brain barrier," Molecular Neurodegeneration, Vol. 8, No. 1, article 22, 2013.
136. E. van der Pol, A. N. Böing, P. Harrison, A. Sturk, and R. Nieuwland, "Classification, functions, and clinical relevance of extracellular vesicles," Pharmacological Reviews, Vol. 64, No. 3, pp. 676-705, 2012.
137. A. M. S. Hartz and B. Bauer, "Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy," Molecular Interventions, Vol. 10, No. 5, pp. 293-304, 2010.
138. Q. Hu, X. Y. Wang, S. Y. Zhu, L. K. Kang, Y. J. Xiao, and H. Y. Zheng, "Meta analysis of contrast enhanced ultrasound for the diferentiation of benign and malignant breast lesions," Acta Radiologica, 2014.
139. J. G. Swan, J. C. Wilbur, K. L. Moodie et al., "Micro bubbles are detected prior to large bubbles following decompression," Journal of Applied Physioliology, Vol. 116, No. 7, pp. 790-796, 2014.
140. C. Tremblay-Darveau, R. Williams, and P. N. Burns, "Measuring absolute blood pressure using microbubbles," Ultrasound in Medicine and Biology, Vol. 40, No. 4, pp. 775-787, 2014.
141. Y. H. Chuang, Y. H. Wang, T. K. Chang, C. J. Lin, and P. C. Li, "Albumin acts like transforming growth factor β1 in microbubble-based drug delivery," Ultrasound in Medcine and Biology, Vol. 40, No. 4, pp. 765-774, 2014.
142. T. Muramoto, R. Shimoya, K. Yoshida, and Y. Watanabe, "Evaluation of the specific adsorption of biotinylated microbubbles using a quartz crystal microbalance," Ultrasound in Medicine and Biology, Vol. 40, No. 5, pp. 1027-1033, 2014.
143. M. Jeon, W. Song, E. Huynh et al., "Methylene blue microbub-bles as a model dual-modality contrast agent for ultrasound and activatable photoacoustic imaging," Journal of Biomed Optics, Vol. 19, No. 1, Article ID 016005, 2014.
144. M. De Saint Victor, C. Crake, C. C. Coussios, and E. Stride, "Properties, characteristics and applications of microbubbles for sonothrombolysis," Expert Opinion in Drug Delivery, Vol. 11, No. 2, pp. 187-209, 2014.
145. A. G. Sorace, M. Korb, J. M. Warram et al., "Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer," Ultrasound in Medicine and Biology, Vol. 40, No. 4, pp. 755-764, 2014.
146. J. S. Oh, Y. S. Kwon, K. H. Lee, W. Jeong, S. K. Chung, and K. Rhee, "Drug perfusion enhancement in tissue model by steady streaming induced by oscillating microbubbles," Computers in Biology and Medicine, Vol. 44, pp. 37-43, 2013.
147. S. L. Gill, H. O'Neill, R. J. McCoy et al., "Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro model," Technology Health Care, Vol. 22, No. 1, pp. 37-51, 2014.
148. W. Tzu-Yin, K. E. Wilson, S. Machtaler, and J. K. Willmann, "Ultrasound and microbubble guided drug delivery: mechanistic understanding and clinical implications," Current Pharmaceutical Biotechnology, Vol. 14, No. 8, pp. 743-752, 2014.
149. N. Hamano, Y. Negishi, K. Takatori et al., "Combination of bubble liposomes and high-intensity focused ultrasound (HIFU) enhanced antitumor effect by tumor ablation," Biological Pharmaceutical Bulletin, Vol. 37, No. 1, pp. 174-177, 2014.
150. S. Stalmans, E. Wynendaele, N. Bracke et al., "Blood-brain barrier transport of short proline-rich antimicrobial peptides," Protein Peptide Letters, Vol. 21, No. 4, pp. 399-406, 2013.
151. Z. Tan, R. C. Turner, R. L. Leon et al., "Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke," Stroke, Vol. 44, No. 12, pp. 3490-3497, 2013.
152. P. E. Milbury and W. Kalt, "Xenobiotic metabolism and berry flavonoid transport across the blood-brain barrier," Journal of Agricultural and Food Chemistry, Vol. 58, No. 7, pp. 3950-3956, 2010.
153. K. Kajimura, Y. Takagi, N. Ueba et al., "Protective effect of Astragali Radix by oral administration against Japanese encephalitis virus infection in mice," Biological & Pharmaceutical Bulletin, Vol. 19, No. 9, pp. 1166-1169, 1996.
154. W. F. Guo and Z. Y. Zhou, "Clinical and experimental study of qing wen oral liquid in the treatment of viral infectious fever," Zhongguo Zhong Xi Yi Jie He Za Zhi, Vol. 12, No. 11, pp. 656-659, 1992.
155. M. Imer, B. Omay, A. Uzunkol et al., "Effect of magnesium, MK-801 and combination of magnesium and MK-801 on blood-brain barrier permeability and brain edema after experimental traumatic difuse brain injury," Neurological research, Vol. 31, No. 9, pp. 977-981, 2009.
156. S. Shrot, G. Markel, T. Dushnitsky, and A. Krivoy, "The possible use of oximes as antidotal therapy in organophosphate-induced brain damage," NeuroToxicology, Vol. 30, No. 2, pp. 167-173, 2009.
157. Z. Songjiang and W. Lixiang, "Amyloid-beta associated with chitosan nano-carrier has flavorable immunogenicity and permeates the BBB," AAPS PharmSciTech, Vol. 10, No. 3, pp. 900-905, 2009.
158. K. M. Sink, X. Leng, J. Williamson et al., "Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the cardiovascular health study," Archives of Internal Medicine, Vol. 169, No. 13, pp. 1195-1202, 2009.
159. M. C. G. Marcondes, C. Flynn, S. Huitron-Rezendiz, D. D. Watry, M. Zandonatti, and H. S. Fox, "Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys," AIDS, Vol. 23, No. 10, pp. 1187-1195, 2009.
160. A. Banerjee, X. Zhang, K. R. Manda, W. A. Banks, and N. Ercal, "HIV proteins (gp120 and That) and methamphetamine in oxidative stress-induced damage in the brain: Potential role of the thiol antioxidant N-acetylcysteine amide," Free Radical Biology and Medicine, Vol. 48, No. 10, pp. 1388-1398, 2010.
161. P. Couvreur, G. Barratt, E. Fattal, P. Legrand, and C. Vauthier, "Nanocapsule technology: a review," Critical Reviews in Tera-peutic Drug Carrier Systems, Vol. 19, No. 2, pp. 99-134, 2002.
162. Y. Liu, J. Tan, A. Thomas, D. Ou-Yang, and V. R. Muzykantov, "The shape of things to come: Importance of design in nan-otechnology for drug delivery," Terapeutic Delivery, Vol. 3, No. 2, pp. 181-194, 2012.
163. G. Barratt, D. Betbeder, and B. Lebleu, "Challenges for nan-otechnology in delivery imaging. Preface," International Journal of Pharmaceutics, Vol. 379, No. 2, pp. 199-200, 2009.
164. S. V. Vinogradov, T. K. Bronich, and A. V. Kabanov, "Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells," Advanced Drug Delivery Reviews, Vol. 54, No. 1, pp. 135-147, 2002.
165. J. K. Sahni, S. Doggui, J. Ali, S. Baboota, L. Dao, and C. Ramassamy, "Neurotherapeutic applications of nanoparticles in Alzheimer's disease," Journal of Controlled Release, Vol. 152, No. 2, pp. 208-231, 2011.
166. J. Kreuter, "Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?" Advances in Drug Delivery Reviews, Vol. 71, pp. 2-14, 2014.
167. C. Vauthier, C. Dubernet, E. Fattal, H. Pinto-Alphandary, and P. Couvreur, "Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications," Advanced Drug Delivery Reviews, Vol. 55, No. 4, pp. 519-548, 2003.
168. S. Jain, W. T. Yap, and D. J. Irvine, "Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and CpG oligonucleotide delivery to antigen-presenting cells," Biomacromolecules, Vol. 6, No. 5, pp. 2590-2600, 2005.
169. M. Üner, "Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostruc-tured lipid carriers (NLC): their benefits as colloidal drug carrier systems," Pharmazie, Vol. 61, No. 5, pp. 375-386, 2006.
170. X. Wang, D. B. Sykes, and D. S. Miller, "Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic eflux transporters at the blood-brain barrier," Molecular Pharmacology, Vol. 78, No. 3, pp. 376-383, 2010.
171. J. Wang, K. Liu, K. C. Sung, C. Tsai, and J. Fang, "Lipid nano-particles with diferent oil/flatty ester ratios as carriers of buprenorphine and its prodrugs for injection," European Journal of Pharmaceutical Sciences, Vol. 38, No. 2, pp. 138-146, 2009.
172. K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, "Biodegradable polymeric nanoparticles as drug delivery devices," Journal of Controlled Release, Vol. 70, No. 1-2, pp. 1-20, 2001.
173. F. Yan, Y. Wang, S. He, S. Ku, W. Gu, and L. Ye, "Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood-brain barrier," Journal of Mater Science Mater Medicine, Vol. 24, No. 10, pp. 2371-2379, 2013.
174. S. A. Agnihotri, N. N. Mallikarjuna, and T. M. Aminabhavi, "Recent advances on chitosan-based micro-and nanoparticles in drug delivery," Journal of Controlled Release, Vol. 100, No. 1, pp. 5-28, 2004.
175. A. K. Banga and Y. W. Chien, "Hydrogel-based iontotherapeutic delivery devices for transdermal delivery of peptide/protein drugs," Pharmaceutical Research, Vol. 10, No. 5, pp. 697-702, 1993.
176. G. Barratt, D. Betbeder, and B. Lebleu, "Challenges for nan-otechnology in delivery imaging, Preface," Intentaional Journal of Pharmacy, Vol. 379, No. 2, pp. 199-200, 2009.
177. S. Wohlfart, A. S. Khalansky, S. Gelperina, D. Begley, and J. Kreuter, "Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier," Journal of Controlled Release, Vol. 154, No. 1, pp. 103-107, 2011.
178. C. C. Müller-Goymann, "Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration," European Journal of Pharmaceutics and Biopharmaceutics, Vol. 58, No. 2, pp. 343-356, 2004.
179. M. Malatesta, M. Giagnacovo, M. Costanzo et al., "Diamino-benzidine photoconversion is a suitable tool for tracking the intracellular location of fluorescently labelled nanoparticles at transmission electron microscopy," European Journal of Histo-chemistry, Vol. 56, No. 2, article e20, 2012.
180. M. A. Rather, R. Sharma, S. Gupta, S. Ferosekhan, V. L. Ramya, and S. B. Jadhao, "Chitosan-nanoconjugated hormone nanopar-ticles for sustained surge of gonadotropins and enhanced reproductive output in female fish," PLoS ONE, Vol. 8, No. 2, Article ID e57094, 2013.
181. R. Mahjub, F. A. Dorkoosh, M. Amini, M. R. Khoshayand, and M. Rafee-Tehrani, "Preparation, statistical optimization, and in vitro characterization of insulin nanoparticles composed of quaternized aromatic derivatives of chitosan," AAPS Pharm-SciTech, Vol. 12, No. 4, pp. 1407-1419, 2011.
182. C. R. Oliveira, C. M. F. Rezende, M. R. Silva, A. P. Pêgo, O. Borges, and A. M. Goes, "A new strategy based on smrho protein loaded chitosan nanoparticles as a candidate oral vaccine against schistosomiasis," PLoS Neglected Tropical Diseases, Vol. 6, No. 11, Article ID e1894, 2012.
183. A. Elsayed, M. Al-Remawi, N. Qinna, A. Farouk, K. A. Al-Sou'Od, and A. A. Badwan, "Chitosan-sodium lauryl sulfate nanoparticles as a carrier system for the in vivo delivery of oral insulin," AAPS PharmSciTech, Vol. 12, No. 3, pp. 958-964, 2011.
184. A. Chaudhury and S. Das, "Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents," AAPS PharmSciTech, Vol. 12, No. 1, pp. 10-20, 2011.
185. H. Hosseinzadeh, F. Atyabi, R. Dinarvand, and S. N. Ostad, "Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study," International Journal of Nanomedicine, Vol. 7, pp. 1851-1863, 2012.
186. M. Alameh, D. de Jesus, M. Jean et al., "Low molecular weight chitosan nanoparticulate system at low N: P ratio for nontoxic polynucleotide delivery," International Journal of Nanomedicine, Vol. 7, pp. 1399-1414, 2012.
187. I. Kadiyala, Y. Loo, K. Roy, J. Rice, and K. W. Leong, "Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes," European Journal of Pharmaceutical Sciences, Vol. 39, No. 1-3, pp. 103-109, 2010.
188. ̄. Özcan, E. Azizoʇlu, T. Şenyiʇit, M. Özyažč, and Ö. Özer, "Enhanced dermal delivery of difucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations," International Journal of Nanomedicine, Vol. 8, pp. 461-475, 2013.
189. A. J. Friedman, J. Phan, D. O. Schairer et al., "Antimicrobial and anti-inflammatory activity of chitosan-alginate nanoparticles: a targeted therapy for cutaneous pathogens," Journal of Investigative Dermatology, Vol. 133, No. 5, pp. 1231-1239, 2013.
190. S.-F. Shi, J.-F. Jia, X.-K. Guo et al., "Biocompatibility of chitosan-coated iron oxide nanoparticles with osteoblast cells," International Journal of Nanomedicine, Vol. 7, pp. 5593-5602, 2012.
191. C. Chung, K. Chung, Y. Jeong, and D. H. Kang, "5-aminolevulinic acid-incorporated nanoparticles of methoxy poly(ethylene glycol)-chitosan copolymer for photodynamic therapy," International Journal of Nanomedicine, Vol. 8, pp. 809-819, 2013.
192. K. Bowman, R. Sarkar, S. Raut, and K. W. Leong, "Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles," Journal of Controlled Release, Vol. 132, No. 3, pp. 252-259, 2008.
193. M. Malhotra, C. Lane, C. Tomaro-Duchesneau, S. Saha, and S. Prakash, "A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis," International Journal of Nanomedicine, Vol. 6, pp. 485-494, 2011.
194. L. Zhang, Z.-L. Zhao, X.-H. Wei, and J.-H. Liu, "Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles," International Journal of Nanomedicine, Vol. 8, pp. 601-610, 2013.
195. T. Yang, D. Nyiawung, A. Silber, J. Hao, L. Lai, and S. Bai, "Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight hep-arin," AAPS PharmSciTech, Vol. 13, No. 4, pp. 1309-1318, 2013.
196. F. Talaei, E. Azizi, R. Dinarvand, and F. Atyabi, "Tiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells," International Journal of Nanomedicine, Vol. 6, pp. 1963-1975, 2011.
197. T. T. Wager, J. L. Liras, S. Mente, and P. Trapa, "Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling," Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, No. 5, pp. 531-542, 2012.
198. J. J. Wang, Z. W. Zeng, R. Z. Xiao et al., "Recent advances of chitosan nanoparticles as drug carriers," International Journal of Nanomedicine, Vol. 6, pp. 765-774, 2011.
199. J. R. Kanwar, B. Sriramoju, and R. K. Kanwar, "Neurological disorders and therapeutics targeted to surmount the blood-brain barrier," International Journal of Nanomedicine, Vol. 7, pp. 3259-3278, 2012.
200. Y. Hu, W. Qi, F. Han, J. Shao, and J. Gao, "Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model," International Journal of Nanomedicine, Vol. 6, pp. 3351-3359, 2011.
201. E. S. Gil, J. Li, H. Xiao, and T. L. Lowe, "Quaternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier," Biomacro-molecules, Vol. 10, No. 3, pp. 505-516, 2009.
202. X. Qian, Y. H. Cheng, D. D. Mruk, and C. Y. Cheng, "Breast cancer resistance protein (Bcrp) and the testis-an unexpected turn of events," Asian Journal of Andrology, Vol. 15, No. 4, pp. 455-460, 2013.
203. A. Figueiras, J. M. G. Sarraguça, A. A. C. C. Pais, R. A. Carvalho, and J. F. Veiga, "The role of l-arginine in inclusion complexes of omeprazole with cyclodextrins," AAPS PharmSciTech, Vol. 11, No. 1, pp. 233-240, 2010.
204. J. Zhang, K. Ellsworth, and P. X. Ma, "Hydrophobic pharmaceuticals mediated self-assembly of beta-cyclodextrin containing hydrophilic copolymers: novel chemical responsive nano-vehicles for drug delivery," Journal of Controlled Release, Vol. 145, No. 2, pp. 116-123, 2010.
205. K. A. Ansari, P. R. Vavia, F. Trotta, and R. Cavalli, "Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study," AAPS PharmSciTech, Vol. 12, No. 1, pp. 279-286, 2011.
206. M. M. Doile, K. A. Fortunato, I. C. Schmücker, S. K. Schucko, M. A. S. Silva, and P. O. Rodrigues, "Physicochemical properties and dissolution studies of dexamethasone acetate-β-cyclodextrin inclusion complexes produced by diferent methods," AAPS PharmSciTech, Vol. 9, No. 1, pp. 314-321, 2008.
207. C. Bisson-Boutelliez, S. Fontanay, C. Finance, and F. Kedzi-erewicz, "Preparation and physicochemical characterization of amoxicillin β-cyclodextrin complexes," AAPS PharmSciTech, Vol. 11, No. 2, pp. 574-581, 2010.
208. K. Songsurang, J. Pakdeebumrung, N. Praphairaksit, and N. Muangsin, "Sustained release of amoxicillin from ethyl cellulose-coated amoxicillin/chitosan-cyclodextrin-based tablets," AAPS PharmSciTech, Vol. 12, No. 1, pp. 35-45, 2011.
209. C. Scarpignato, "Piroxicam-beta-cyclodextrin: a GI safer pirox-icam," Current Medicinal Chemistry, Vol. 20, No. 19, pp. 2415-2437, 2013.
210. H. Yano and P. Kleinebudde, "Improvement of dissolution behavior for poorly water-soluble drug by application of cyclodextrin in extrusion process: Comparison between melt extrusion and wet extrusion," AAPS PharmSciTech, Vol. 11, No. 2, pp. 885-893, 2010.
211. P. R. Dandawate, A. Vyas, A. Ahmad et al., "Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer," Pharmaceutical Research, Vol. 29, No. 7, pp. 1775-1786, 2012.
212. 7β-CD) carbamazepine complex: Preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity," AAPS PharmSciTech, Vol. 12, No. 4, pp. 1163-1175, 2011.
213. I. F. Harrison and D. T. Dexter, "Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?" Pharmacology and Terapeutics, Vol. 140, No. 1, pp. 34-52, 2013.
214. D. S. Miller, "Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier," Trends in Pharmacological Sciences, Vol. 31, No. 6, pp. 246-254, 2010.
215. 11C] Methyl Derivative of 6, 7-Dimethoxy-2-(4-Methoxy-Biphenyl-4-yl-Methyl)-1, 2, 3, 4-Tetrahydro-Isoquino-line, National Center for Biotechnology Information, Bethesda, Md, USA, 2012.
216. M. Tachikawa, Y. Uchida, and T. Terasaki, "Multi-disciplinary research approaches on the brain barrier transport system, a dynamic interface," Brain and Nerve, Vol. 65, No. 2, pp. 121-136, 2013.
217. S. Pilakka-Kanthikeel, V. S. R. Atluri, V. Sagar, and M. Nair, "Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study," PLoS ONE, Vol. 8, No. 4, Article ID e62241, 2013.
218. A. Puri, K. Loomis, B. Smith et al., "Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic," Critical Reviews in Terapeutic Drug Carrier Systems, Vol. 26, No. 6, pp. 523-580, 2009.
219. S. Martins, B. Sarmento, D. C. Ferreira, and E. B. Souto, "Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles," International Journal of Nanomedicine, Vol. 2, No. 4, pp. 595-607, 2007.
220. R. Diab, C. Jaafar-Maalej, H. Fessi, and P. Maincent, "Engineered nanoparticulate drug delivery systems: the next frontier for oral administration," AAPS Journal, Vol. 14, No. 4, pp. 688-702, 2012.
221. S. K. Nitta and K. Numata, "Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering," International Journal of Molecular Sciences, Vol. 14, No. 1, pp. 1629-1654, 2013.
222. D. N. Nguyen, K. P. Mahon, G. Chikh et al., "Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery," Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 14, pp. E797-E803, 2012.
223. P. Desai, R. R. Patlolla, and M. Singh, "Interaction of nanopar-ticles and cell-penetrating peptides with skin for transdermal drug delivery," Molecular Membrane Biology, Vol. 27, No. 7, pp. 247-259, 2010.
224. O. Le Bihan, R. Chèvre, S. Mornet, B. Garnier, B. Pitard, and O. Lambert, "Probing the in vitro mechanism of action of cationic lipid/DNA lipoplexes at a nanometric scale," Nucleic Acids Research, Vol. 39, No. 4, pp. 1595-1609, 2011.
225. H. Sah, L. A. Toma, H. R. Desu, E. Sah, and G. C. Wood, "Concepts and practices used to develop functional PLGA-based nanoparticulate systems," International Journal of Nanomedicine, Vol. 8, pp. 747-765, 2013.
226. A. Yavlovich, B. Smith, K. Gupta, R. Blumenthal, and A. Puri, "Light-sensitive lipid-based nanoparticles for drug delivery: Design principles and future considerations for biological applications," Molecular Membrane Biology, Vol. 27, No. 7, pp. 364-381, 2010.
227. S. Ramishetti and L. Huang, "Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy," Terapeutic Delivery, Vol. 3, No. 12, pp. 1429-1445, 2012.
228. M. T. Nyunt, C. W. Dicus, Y. Cui et al., "Physico-chemical characterization of polylipid nanoparticles for gene delivery to the liver," Bioconjugate Chemistry, Vol. 20, No. 11, pp. 2047-2054, 2009.
229. Q. Huang, G. Zhong, Y. Zhang et al., "Cyclen-based cationic lipids for highly efficient gene delivery towards tumor cells," PLoS ONE, Vol. 6, No. 8, Article ID e23134, 2011.
230. X.-X. Zhang, T. J. McIntosh, and M. W. Grinstaf, "Functional lipids and lipoplexes for improved gene delivery," Biochimie, Vol. 94, No. 1, pp. 42-58, 2012.
231. F. C. Pérez-Martínez, J. Guerra, I. Posadas, and V. Ceña, "Barriers to non-viral vector-mediated gene delivery in the nervous system," Pharmaceutical Research, Vol. 28, No. 8, pp. 1843-1858, 2011.
232. T. R. Kuo, D. Y. Wang, Y. C. Chiu et al., "Layer-by-layer thin film of reduced graphene oxide and gold nanoparticles as an effective sample plate in laser-induced desorption/ionization mass spectrometry," Analytica Chimica Acta, Vol. 809, pp. 97-103, 2014.
233. Y.-C. Kuo and C.-C. Wang, "Cationic solid lipid nanoparticles with cholesterol - mediated surface layer for transporting saquinavir to the brain," Biotechnology Progress, Vol. 30, No. 1, pp. 198-206, 2014.
234. C. Cornacchia, I. Cacciatore, L. Baldassarre, A. Mollica, F. Feliciani, and F. Pinnen, "2, 5-Diketopiperazines as neuroprotective agents," Medicinal Chemistry, Vol. 12, No. 1, pp. 2-12, 2012.
235. I. J. Fidler, "The role of the organ microenvironment in brain metastasis," Seminars in Cancer Biology, Vol. 21, No. 2, pp. 107-112, 2011.
236. A. Prokop and J. M. Davidson, "Nanovehicular intracellular delivery systems," Journal of Pharmaceutical Sciences, Vol. 97, No. 9, pp. 3518-3590, 2008.
237. M. Roger, A. Clavreul, M. C. Venier-Julienne, C. Passirani, C. Montero-Menei, and P. Menei, "The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy," Biomaterials, Vol. 32, No. 8, pp. 2106-2116, 2011.
238. E. Miele, G. P. Spinelli, E. D. Fabrizio, E. Ferretti, S. Tomao, and A. Gulino, "Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy," International Journal of Nanomedicine, Vol. 7, pp. 3637-3657, 2012.
239. B. Ozpolat, A. K. Sood, and G. Lopez-Berestein, "Liposomal siRNA nanocarriers for cancer therapy," Advances in Drug Delivery Review, Vol. 66, pp. 110-116, 2014.
240. Y. Chen, X. Zhu, X. Zhang, B. Liu, and L. Huang, "Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy," Molecular Therapy, Vol. 18, No. 9, pp. 1650-1656, 2010.
241. B. Pulford, N. Reim, A. Bell et al., "Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrPC on neuronal cells and PrPRES in infected cell cultures," PLoS ONE, Vol. 5, No. 6, Article ID e11085, 2010.
242. S. Ding and R. Lu, "Virus-derived siRNAs and piRNAs in immunity and pathogenesis," Current Opinion in Virology, Vol. 1, No. 6, pp. 533-544, 2011.
243. J. L Li, X. Hou, Y. Liu et al., "Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas," Biomaterials, Vol. 35, No. 12, pp. 3840-3850, 2014.
244. P. S. Kowalski, P. J. Zwiers, H. W. Morselt et al., "Anti-VCAM-1 SAINT-O-Somes enable endothelial-specific delivery of siRNA and downregulation of inflammatory genes in activated endothelium In vivo," Journal of Control Release, Vol. 176C, pp. 64-75, 2014.
245. C. Gonτalves, M. Berchel, M. P. Gosselin et al., "Lipopoly-plexes comprising imidazole/imidazolium lipophosphorami-date, histidinylated polyethyleneimine and siRNA as efficient formulation for siRNA transfection," International Journal of Pharmaceutics, Vol. 460, No. 1-2, pp. 264-272, 2013.
246. Z. Dai, M. T. Arévalo, J. Li, and M. Zeng, "Addition of poly (propylene glycol) to multiblock copolymer to optimize siRNA delivery," Bioengineered, Vol. 5, No. 1, pp. 30-37, 2014.
247. J. Wang, Z. Lu, B. Z. Yeung, M. G. Wientjes, D. J. Cole, and J. L.-S. Au, "Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors," Journal of Control Release, Vol. 178, pp. 79-85, 2014.
248. T. Tsujiuchi, A. Natsume, K. Motomura et al., "Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains," The American Journal of Translational Research, Vol. 6, No. 2, pp. 169-178, 2014.
249. S.Y. Wu and N.A. McMillan, "Lipidic systems florin vivo siRNA delivery," The AAPS Journal, Vol. 11, No. 4, pp. 639-652, 2009.
250. G. M. Barratt, "Terapeutic applications of colloidal drug carriers," Pharmaceutical Science & Technology Today, Vol. 3, No. 5, pp. 163-171, 2000.
251. W. N. Charman, H. K. Chan, B. C. Finnin, and S. A. Charman, "Drug delivery: a key factor in realising the full therapeutic potential of drugs," Drug Development Research, Vol. 46, pp. 316-327, 1999.
252. J. T. Santini Jr., A. C. Richards, R. Scheidt, M. J. Cima, and R. Langer, "Microchips as controlled drug-delivery devices," Angewandte Chemie International Edition, Vol. 39, No. 14, pp. 2396-2407, 2000.
253. S. Asthana, P. K. Gupta, M. Chaurasia, A. Dube, and M. K. Chourasia, "Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos," Expert Opinion in Drug Delivery, Vol. 10, No. 12, pp. 1633-1651, 2013.
254. J. Chen, W. T. Dai, Z. M. He et al., "Fabrication and evaluation of curcumin-loaded nanoparticles based on solid lipid as a new type of colloidal drug delivery system," Indian Journal of Pharmaceutical Sciences, Vol. 75, No. 2, pp. 178-184, 2013.
255. R. M. Hathout, "Using principal component analysis in studying the transdermal delivery of a lipophilic drug from soft nano-colloidal carriers to develop a quantitative composition effect permeability relationship," Pharmaceutical and Development Technology, Vol. 19, No. 5, pp. 598-604, 2014.
256. M. Jaganathan, D. Madhumitha, and A. Dhathathreyan, "Protein microcapsules: preparation and applications," Advances in Colloid Interface Science, Vol. 209, pp. 1-7, 2014.
257. E. E. Paoli, E. S. Ingham, H. Zhang et al., "Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes," Journal of Control Release, Vol. 178, pp. 108-117, 2014.
258. C. N. Sanchez-Dominguez, H. L. Gallardo-Blanco, A. A. Rodriguez-Rodriguez, A. V. Vela-Gonzalez, and M. Sanchez-Dominguez, "Nanoparticles vs cancer: a multifuncional tool," Current Topics in Medicinal Chemistry, Vol. 14, No. 5, pp. 664-675, 2014.
259. A. López-Noriega, C. L. Hastings, B. Ozbakir et al., "Hyperther-mia-induced drug delivery from thermosensitive liposomes encapsulated in an injectable hydrogel for local chemothera-pyefectiveness of variable message signs on driving behavior based on a driving simulation experiment," Advances in Healthcare Materials, 2014.
260. K. Ninomiya, T. Yamashita, S. Kawabata, and N. Shimizu, "Targeted and ultrasound-triggered drug delivery using liposomes co-modified with cancer cell-targeting aptamers and a thermosensitive polymer," Ultrasonic Sonochemistry, Vol. 21, No. 4, pp. 1482-1488, 2014.
261. M. S. Kim, D. W. Lee, K. Park et al., "Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-con-jugated thermosensitive liposomes," Colloids and Surfaces B: Biointerfaces, Vol. 116, pp. 17-25, 2013.
262. N. K. Mittal, H. Bhattacharjee, B. Mandal, P. Balabathula, L. A. Toma, and G. C. Wood, "Targeted liposomal drug delivery systems for the treatment of B cell malignancies," Journal of Drug Targeting, Vol. 22, No. 5, pp. 372-386, 2014.
263. L. Zhang, D. Y. Cao, J. Wang et al., "PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals," European Review Medicinal Pharmacological Sciences, Vol. 17, No. 24, pp. 3347-3361, 2013.
264. B. Sudhakar, J. N. Varma, and K. V. Murthy, "Formulation, characterization and ex vivo studies of terbinafine HCl liposomes for cutaneous delivery," Current Drug Delivery, Vol. 11, No. 4, pp. 521-530, 2014.
265. K. K. Sarwa, P. K. Suresh, M. Rudrapal, and V. K. Verma, "Penetration of tamoxifen citrate loaded ethosomes and liposomes across human skin: a comparative study with confocal laser scanning microscopy," Current Drug Delivery, Vol. 11, No. 3, pp. 332-337, 2014.
266. M. Safari, F. H. Shirazi, M. A. Oghabian, and H. R. Moghimi, "Preparation and in-vitro evaluation of an antisense-containing cationic liposome against non-small cell lung cancer: a comparative preparation study," Iranian Journal of Pharmaceutical Research, Vol. 12, supplement, pp. 3-10, 2013.
267. H. Ding, V. Sagar, M. Agudelo et al., "Enhanced blood-brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation," Nanotechnology, Vol. 25, No. 5, Article ID 055101, 2014.
268. J. Tang, H. Fu, Q. Kuang et al., "Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery," Journal of Drug Targeting, Vol. 22, No. 4, pp. 313-316, 2014.
269. A. D. Tagalakis, G. D. Kenny, A. S. Bienemann et al., "PEGy-lation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes," Journal of Control Release, Vol. 174, pp. 177-187, 2014.
270. A. A. Yaroslavov, A. V. Sybachin, O. V. Zaborova et al., "Electrostatically driven complexation of liposomes with a star-shaped polyelectrolyte to low-toxicity multi-liposomal assemblies," Macromolecular Bioscience, Vol. 14, No. 4, pp. 491-495, 2014.
271. P. Vabbilisetty and X. L. Sun, "Liposome surface functionalization based on diferent anchoring lipids via Staudinger ligation," Organic Biomolecular Chemistry, Vol. 12, pp. 1237-1244, 2014.
272. N. Yamamoto and A. Tamura, "Designing cell-aggregating peptides without cytotoxicity," Biomacromolecules, Vol. 15, No. 2, pp. 512-523, 2014.
273. A. Rösler, G. W. M. Vandermeulen, and H. A. Klok, "Advanced drug delivery devices via self-assembly of amphiphilic block copolymers," Advanced Drug Delivery Reviews, Vol. 53, No. 1, pp. 95-108, 2001.
274. M. M. Gaspar, A. F. Penha, A. C. Sousa et al., Proceed. 7th Liposomes Advances, Progress in Drug and Vaccine Delivery, School of Pharmacy, London, UK, 2005.
275. E. M. Cornford, L. D. Braun, W. H. Oldendorf, and M. A. Hill, "Comparison of lipid-mediated blood-brain barrier penetrability in neonates and adults," American Journal of Physiology, Vol. 243, No. 3, pp. C161-C168, 1982.
276. L. Li, J. Hou, X. Liu et al., "Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas," Biomaterials, Vol. 35, No. 12, pp. 3840-3850, 2014.
277. M. El-Badry, G. Fetih, and F. Shakeel, "Comparative topical delivery of antifungal drug croconazole using liposome and micro-emulsion-based gel formulations," Drug Delivery, Vol. 21, No. 1, pp. 34-43, 2014.
278. N. Anton and T. F. Vandamme, "Nano-emulsions and micro-emulsions: clarifications of the critical diferences," Pharmaceutical Research, Vol. 28, No. 5, pp. 978-985, 2011.
279. W. He, X. Guo, M. Feng, and N. Mao, "In vitro and in vivo studies on ocular vitamin A palmitate cationic liposomal in situ gels," International Journal of Pharmaceutics, Vol. 458, No. 2, pp. 305-314, 2013.
280. A. S. Abu Lila, Y. Uehara, T. Ishida, and H. Kiwada, "Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery," Journal of Pharmaceutical Science, Vol. 103, No. 2, pp. 557-566, 2013.
281. R. Deng and J. P. Balthasar, "Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunother-apy in a murine model of passive chronic immune thrombocy-topenia," Blood, Vol. 109, No. 6, pp. 2470-2476, 2007.
282. S. R. Sarker, R. Hokama, and S. Takeoka, "Intracellular delivery of universal proteins using a lysine headgroup containing cationic liposomes: deciphering the uptake mechanism," Molecular Pharmacology, Vol. 11, No. 1, pp. 164-174, 2014.
283. G. Weissmann, A. Brand, and E. C. Franklin, "Interaction of immunoglobulins with liposomes," The Journal of Clinical Investigation, Vol. 53, No. 2, pp. 536-543, 1974.
284. J. Gao, H. Chen, H. Song et al., "Antibody-targeted immunoli-posomes for cancer treatment," Journal of Medicinal Chemistry, Vol. 13, No. 14, pp. 2026-2035, 2013.
285. N. Okada, T. Yasuda, T. Tsumita, and H. Okada, "Membrane sialoglycolipids regulate the activation of the alternative complement pathway by liposomes containing trinitro-phenylaminocaproyldipalmitoylphosphatidylethanolamine," Immunology, Vol. 48, No. 1, pp. 129-140, 1983.
286. R. R. Rando, J. Slama, and F. W. Bangerter, "Functional incorporation of synthetic glycolipids into cells," Proceedings of the National Academy of Sciences of the United States of America, Vol. 77, No. 5, pp. 2510-2513, 1980.
287. Y. Ohtsubo, M. Furukawa, T. Imagawa et al., "Growth inhibition of tumour cells by a liposome-encapsulated mycolic acid-containing glycolipid, trehalose 2, 3, 6'-trimycolate," Immunology, Vol. 74, No. 3, pp. 497-503, 1991.
288. S. Steinert, E. Lee, G. Tresset et al., "A fluorescent glycolipid-binding peptide probe traces cholesterol dependent microd-omain-derived traficking pathways," PLoS ONE, Vol. 3, No. 8, Article ID e2933, 2008.
289. S. Biswas, N. S. Dodwadkar, R. R. Sawant, and V. P. Torchilin, "Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization," Bioconjugate Chemistry, Vol. 22, No. 10, pp. 2005-2013, 2011.
290. Y. Li, T. Su, Y. Zhang, X. Huang, J. Li, and C. Li, "Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistant Staphylococ-cus aureus infection," Drug Delivery, 2014.
291. D. S. Pisal, M. P. Kosloski, and S. V. Balu-Iyer, "Delivery of therapeutic proteins," Journal of Pharmaceutical Sciences, Vol. 99, No. 6, pp. 2557-2575, 2010.
292. K. Gradauer, S. Dünnhaupt, C. Vonach et al., "Tiomer-coated liposomes harbor permeation enhancing and eflux pump inhibitory properties," Journal of Controlled Release, Vol. 165, No. 3, pp. 207-215, 2013.
293. R. Srinivasan, R. E. Marchant, and A. S. Gupta, "in vitro and In vivo platelet targeting by cyclic RGD-modified liposomes," Journal of Biomedical Materials Research A, Vol. 93, No. 3, pp. 1004-1015, 2010.
294. C.-W. Chen, D.-W. Lu, M.-K. Yeh, C.-Y. Shiau, and C.-H. Chiang, "Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells," International Journal of Nanomedicine, Vol. 6, pp. 2567-2580, 2011.
295. E. Junquera and E. Aicart, "Cationic lipids as transfecting agents of DNA in gene therapy," Current Topics in Medicinal Chemistry, Vol. 14, No. 5, pp. 649-663, 2014.
296. M. D. Howard, C. F. Greineder, E. D. Hood, and V. R. Muz-ykantov, "Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation," Journal of Control Release, Vol. 177, pp. 34-41, 2014.
297. R. Haag, "Supramolecular drug-delivery systems based on polymeric core-shell architectures," Angewandte Chemie-International Edition, Vol. 43, No. 3, pp. 278-282, 2004.
298. C. Alvarez-Lorenzo and A. Concheiro, "Molecularly imprinted polymers for drug delivery," Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 804, No. 1, pp. 231-245, 2004.
299. M. Winterhalter, C. Hilty, S. M. Bezrukov, C. Nardin, W. Meier, and D. Fournier, "Controlling membrane permeability with bacterial porins: application to encapsulated enzymes," Talanta, Vol. 55, No. 5, pp. 965-971, 2001.
300. J. K. Vasir, K. Tambwekar, and S. Garg, "Bioadhesive micro-spheres as a controlled drug delivery system," International Journal of Pharmaceutics, Vol. 255, No. 1-2, pp. 13-32, 2003.
301. M. E. Byrne, K. Park, and N. A. Peppas, "Molecular imprinting within hydrogels," Advanced Drug Delivery Reviews, Vol. 54, No. 1, pp. 149-161, 2002.
302. J. W. Park, C. C. Benz, and F. J. Martin, "Future directions of liposome-and immunoliposome-based cancer therapeutics," Seminars in Oncology, Vol. 31, No. 6, supplement 13, pp. 196-205, 2004.
303. Y. Bae, S. Fukushima, A. Harada, and K. Kataoka, "Design of environment-sensitive supramolecular assemblies for intra-cellular drug delivery: polymeric micelles that are responsive to intracellular pH change," Angewandte Chemie International Edition, Vol. 42, No. 38, pp. 4640-4643, 2003.
304. N. M. Dand, P. B. Patel, A. P. Ayre, and V. J. Kadam, "Polymeric micelles as a drug carrier for tumor targeting," Chronicles of Young Scientists, Vol. 4, No. 2, pp. 94-101, 2013.
305. M. Yokoyama, "Polymeric micelles as a new drug carrier system and their required considerations for clinical trials," Expert Opinion on Drug Delivery, Vol. 7, No. 2, pp. 145-158, 2010.
306. M. Jones and J. Leroux, "Polymeric micelles: a new generation of colloidal drug carriers," European Journal of Pharmaceutics and Biopharmaceutics, Vol. 48, No. 2, pp. 101-111, 1999.
307. M. Mazza, R. Notman, J. Anwar et al., "Nanofiber-based delivery of therapeutic peptides to the brain," ACS Nano, Vol. 7, No. 2, pp. 1016-1026, 2013.
308. B. Lee, T. Amano, H. Q. Wang et al., "Reactive oxygen species responsive nanoprodrug to treat intracranial glioblastoma," ACS Nano, Vol. 7, No. 4, pp. 3061-3077, 2013.
309. D. T. Wiley, P. Webster, A. Gale, and M. E. Davis, "Transcy-tosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor," Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 21, pp. 8662-8667, 2013.
310. A. D. Jeyasekharan, Y. Liu, H. Hattori et al., "A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization," Nature Structural & Molecular Biology, Vol. 20, No. 10, pp. 1191-1198, 2013.
311. A. Jain, A. Jain, A. Gulbake, S. Shilpi, P. Hurkat, and S. K. Jain, "Peptide and protein delivery using new drug delivery systems," Critical Reviews in Terapeutic Drug Carrier Systems, Vol. 30, No. 4, pp. 293-329, 2013.